𝛼SK or Searchbearish
Primer: Actinium Pharmaceuticals (ATNM US) - Aug 2026
91 Views09 Aug 2026 17:00
Actinium's lead candidate, Iomab-B, faced a significant setback in August 2024 when the FDA determined the Phase 3 SIERRA trial data was...
What is covered in the Full Insight:
- Company Overview
- Key Products And Services
- Management
- Key Positives and Watch-Outs
- Industry and Competitive Landscape Overview
SUMMARY
(Sign Up to Access)Sign up for free to unlock the full Primer (no credit card required)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 10-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Primer: Actinium Pharmaceuticals (ATNM US) - Aug 202609 Aug 2026
x